The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | A trial investigating IberVd in transplant-ineligible newly diagnosed multiple myeloma
Sagar Lonial, MD, FACP, Emory University School of Medicine, Atlanta, GA, discusses a trial investigating the combination of iberdomide, bortezomib, and dexamethasone (IberVd) in newly diagnosed transplant-ineligible multiple myeloma. The results were promising, with significant numbers of patients achieving measurable residual disease (MRD) negativity. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, a trial that I think we’re very excited about is the iber-bortezomib-dex trial, which was an arm of the original Phase I study for iberdomide. And this was a newly diagnosed arm where iberdomide was combined with bortezomib, similar to sort of an RVd concept, only using the newer CELMoD iberdomide as part of it. And what we saw in this was a very high overall response rate, 100% of patients had a response...
Yeah, a trial that I think we’re very excited about is the iber-bortezomib-dex trial, which was an arm of the original Phase I study for iberdomide. And this was a newly diagnosed arm where iberdomide was combined with bortezomib, similar to sort of an RVd concept, only using the newer CELMoD iberdomide as part of it. And what we saw in this was a very high overall response rate, 100% of patients had a response. We saw significant numbers of patients achieving MRD negativity. And certainly the PFS looks as good, if not better, than what we’ve seen for VRd in a similar group of patients in large randomized Phase III trials. I think what this really suggests to me is that the potency of an agent like iberdomide, the CELMoD category, is clearly greater than what we see with len or pom, and that it does, in fact, make a good treatment partner with bortezomib and with anti-CD38s, as in other trials that have been presented in the context of newly diagnosed myeloma.
Read more...
